Trial Profile
An open-label, phase II study of Overex Mab-B43.13 [oregovomab] as an adjuvant treatment to platinum-based front-line chemotherapy of advanced epithelial carcinoma of ovarian, tubal, or peritoneal origin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Oregovomab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics; Therapeutic Use
- 22 Jan 2009 Status changed from discontinued to completed.
- 22 Jan 2009 Results were reported in J Immunother in Jan 2009.
- 21 Jan 2009 Primary endpoint 'Immunological response' has been met.